济川药业
(600566)
| 流通市值：402.56亿 | | | 总市值：405.23亿 |
| 流通股本：9.16亿 | | | 总股本：9.22亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,402,545,954.32 | 9,654,537,192.67 | 6,536,764,954.98 | 4,628,976,049.33 |
| 营业收入 | 2,402,545,954.32 | 9,654,537,192.67 | 6,536,764,954.98 | 4,628,976,049.33 |
| 二、营业总成本 | 1,594,276,317.54 | 6,516,457,726.29 | 4,458,429,019.85 | 3,213,238,134.65 |
| 营业成本 | 453,698,653.45 | 1,783,993,372.03 | 1,196,642,437.11 | 850,079,433.97 |
| 税金及附加 | 38,740,096.81 | 146,238,497.23 | 99,529,573.94 | 70,618,265.21 |
| 销售费用 | 989,645,386.93 | 4,006,536,051.96 | 2,719,010,883.2 | 2,001,540,637.1 |
| 管理费用 | 91,736,719.04 | 372,779,034.03 | 278,947,911.96 | 180,869,408.52 |
| 研发费用 | 114,221,835.9 | 464,400,198.6 | 334,603,477.5 | 215,064,509.7 |
| 财务费用 | -93,766,374.59 | -257,489,427.56 | -170,305,263.86 | -104,934,119.85 |
| 其中:利息费用 | 7,550,518.45 | 17,583,918.49 | 9,987,665.41 | 6,556,973.41 |
| 其中:利息收入 | 101,596,444.51 | 276,084,305.02 | 180,962,191.99 | 111,935,679.13 |
| 加:公允价值变动收益 | 16,232,067.88 | 14,603,985.81 | 15,537,119.02 | 20,903,837.88 |
| 加:投资收益 | 14,744,804.02 | 81,723,599.77 | 76,641,079.52 | 51,332,101.14 |
| 资产处置收益 | -5,944.01 | 130,280.19 | 100,944.71 | 93,330.43 |
| 信用减值损失(新) | 41,482,263.78 | 3,225,543.75 | 42,613,248.89 | 36,540,946.65 |
| 其他收益 | 5,202,341.01 | 20,372,895.9 | 11,455,203.92 | 7,573,521.57 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 885,925,169.46 | 3,258,135,771.8 | 2,224,683,531.19 | 1,532,181,652.35 |
| 加:营业外收入 | 103,965,583.27 | 41,644,609.74 | 36,056,390.39 | 32,438,038.1 |
| 减:营业外支出 | 100,588.51 | 2,690,791.34 | 1,164,264.71 | 2,153,075.25 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 989,790,164.22 | 3,297,089,590.2 | 2,259,575,656.87 | 1,562,466,615.2 |
| 减:所得税费用 | 143,002,860.11 | 470,026,598.95 | 312,195,783.23 | 220,408,841.14 |
| 六、净利润 | 846,787,304.11 | 2,827,062,991.25 | 1,947,379,873.64 | 1,342,057,774.06 |
| 持续经营净利润 | 846,787,304.11 | 2,827,062,991.25 | 1,947,379,873.64 | 1,342,057,774.06 |
| 归属于母公司股东的净利润 | 845,266,461.66 | 2,822,781,164.62 | 1,944,157,913.66 | 1,339,843,900.4 |
| 少数股东损益 | 1,520,842.45 | 4,281,826.63 | 3,221,959.98 | 2,213,873.66 |
| (一)基本每股收益 | 0.92 | 3.08 | 2.12 | 1.46 |
| (二)稀释每股收益 | 0.92 | 3.08 | 2.12 | 1.46 |
| 九、综合收益总额 | 846,787,304.11 | 2,827,062,991.25 | 1,947,379,873.64 | 1,342,057,774.06 |
| 归属于母公司股东的综合收益总额 | 845,266,461.66 | 2,822,781,164.62 | 1,944,157,913.66 | 1,339,843,900.4 |
| 归属于少数股东的综合收益总额 | 1,520,842.45 | 4,281,826.63 | 3,221,959.98 | 2,213,873.66 |
| 公告日期 | 2024-04-20 | 2024-04-10 | 2023-10-23 | 2023-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |